<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459080</url>
  </required_header>
  <id_info>
    <org_study_id>0126</org_study_id>
    <nct_id>NCT02459080</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>COPD</acronym>
  <official_title>A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effectiveness and safety of TD 4208, an
      investigational drug being developed to treat people with moderate to very severe COPD,
      compared to placebo, a treatment without activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 on Day 85</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Trough FEV1 Overall Treatment Effect From Day 15 to Day 85</measure>
    <time_frame>Days 15 to 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline to Peak FEV1 After First Dose</measure>
    <time_frame>0-2 hours after First Dose Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Rescue Medication Use: Puffs Per Day</measure>
    <time_frame>1-3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Albuterol Rescue-free 24-hour Periods</measure>
    <time_frame>1-3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Proportion of Responders on Day 85</measure>
    <time_frame>Baseline to Day 85</time_frame>
    <description>A Responder is defined as someone who experienced a decrease in SGRQ score of 4 or more units</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">619</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>TD-4208-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>88 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-4208-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>175 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208</intervention_name>
    <arm_group_label>TD-4208-1</arm_group_label>
    <arm_group_label>TD-4208-2</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Associates Research Center (AARC)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2015</study_first_posted>
  <results_first_submitted>December 6, 2018</results_first_submitted>
  <results_first_submitted_qc>December 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2018</results_first_posted>
  <disposition_first_submitted>February 22, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 22, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 26, 2018</disposition_first_posted>
  <last_update_submitted>January 26, 2019</last_update_submitted>
  <last_update_submitted_qc>January 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease, COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TD-4208-1</title>
          <description>88 mcg
TD-4208</description>
        </group>
        <group group_id="P2">
          <title>TD-4208-2</title>
          <description>175 mcg
TD-4208</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TD-4208-1</title>
          <description>88 mcg
TD-4208</description>
        </group>
        <group group_id="B2">
          <title>TD-4208-2</title>
          <description>175 mcg
TD-4208</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="209"/>
            <count group_id="B4" value="619"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.90"/>
                    <measurement group_id="B2" value="64.2" spread="8.60"/>
                    <measurement group_id="B3" value="64.3" spread="9.12"/>
                    <measurement group_id="B4" value="64.1" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="204"/>
                    <measurement group_id="B4" value="595"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="564"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 on Day 85</title>
        <time_frame>Day 85</time_frame>
        <population>Intent-to-treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 on Day 85</title>
          <population>Intent-to-treat (ITT) analysis set</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.81" spread="15.095"/>
                    <measurement group_id="O2" value="126.85" spread="15.389"/>
                    <measurement group_id="O3" value="-19.41" spread="16.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Trough FEV1 Overall Treatment Effect From Day 15 to Day 85</title>
        <time_frame>Days 15 to 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Trough FEV1 Overall Treatment Effect From Day 15 to Day 85</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="3.10"/>
                    <measurement group_id="O2" value="124.8" spread="3.20"/>
                    <measurement group_id="O3" value="-30.8" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline to Peak FEV1 After First Dose</title>
        <time_frame>0-2 hours after First Dose Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline to Peak FEV1 After First Dose</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.14" spread="9.546"/>
                    <measurement group_id="O2" value="224.46" spread="9.744"/>
                    <measurement group_id="O3" value="91.79" spread="9.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Rescue Medication Use: Puffs Per Day</title>
        <time_frame>1-3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Rescue Medication Use: Puffs Per Day</title>
          <units>Puffs per Day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.234"/>
                    <measurement group_id="O2" value="2.27" spread="0.239"/>
                    <measurement group_id="O3" value="2.72" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Albuterol Rescue-free 24-hour Periods</title>
        <time_frame>1-3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Albuterol Rescue-free 24-hour Periods</title>
          <units>Percentage of 24 hr periods</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.35" spread="2.784"/>
                    <measurement group_id="O2" value="43.57" spread="2.829"/>
                    <measurement group_id="O3" value="45.21" spread="2.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Proportion of Responders on Day 85</title>
        <description>A Responder is defined as someone who experienced a decrease in SGRQ score of 4 or more units</description>
        <time_frame>Baseline to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-4208-1</title>
            <description>88 mcg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>TD-4208-2</title>
            <description>175 mcg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Proportion of Responders on Day 85</title>
          <description>A Responder is defined as someone who experienced a decrease in SGRQ score of 4 or more units</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of ICF through the final follow-up assessment, Day 85.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TD-4208-1</title>
          <description>88 mcg
TD-4208</description>
        </group>
        <group group_id="E2">
          <title>TD-4208-2</title>
          <description>175 mcg
TD-4208</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gastric volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="212"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development &amp; Medical Affairs</name_or_title>
      <organization>Theravance Biopharma</organization>
      <phone>1-855-633-8479</phone>
      <email>medinfo@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

